Serious toxicity associated with continuous nevirapine-based HAART in pregnancy

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 115, Issue 10, 2008, Pages 1297-1302

  Van Schalkwyk, J E ^a,b   Alimenti, A ^a,b   Khoo, D ^a   Maan, E ^a   Forbes, J C ^a,b   Burdge, D R ^a,b,c   Gilgoff, S ^a   Money, D M ^a,b,c  

^a CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c WOMEN S HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

Continuous nevirapine; HAART; Pregnancy; Toxicity

Indexed keywords

AMINOTRANSFERASE; DIDANOSINE; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; STAVUDINE;

ABORIGINE; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANADA; CD4+ T LYMPHOCYTE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NEGRO; NEPHROLITHIASIS; POPULATION RESEARCH; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; MULTIVARIATE ANALYSIS; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES;

EID: 49649122026     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2008.01820.x     Document Type: Article

References (15)

1. Perinatal HIV Guidelines Working Group, USA. Public Health Service Task Force. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. United States Department of Health and Human Services. 2007 http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf Accessed 19 December 2007.
2. Burdge DR, Money DM, Forbes JC, Walmsley SL, Smaill FM, Boucher M, et al. Canadian consensus guidelines for the management of pregnancy, labor and delivery and for post-partum care in HIV-positive women and their offspring (summary of 2002 guidelines). CMAJ 2003 168 : 1671 4.
3. Panel on Antiretroviral Guidelines for Adult and Adolescents, USA. Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents. United States Department of Health and Human Services. 2007 www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf Accessed 19 December 2007.
4. Hitti J, Frenkel LM, Stek AM, Nachman SA, Baker D, Gonzalez-Garcia A, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr 2004 36 : 772 6.
5. United States Food and Drug Administration. FDA public health advisory for nevirapine (Viramune). 2005 www.fda.gov/cder/drug/advisory/nevirapine.htm Accessed 19 December 2007.
6. Lyones F, Hopkins S, Kelleher B, McGeary A, Sheehan G, Geoghegan J, et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral medication in pregnancy. HIV Med 2006 7 : 255 60.
7. Natarajan U, Pym A, McDonald C, Velisetty P, Edwards SG, Hay P, et al. Safety of nevirapine in pregnancy. HIV Med 2007 8 : 64 9.
8. Jamisse L, Balkus J, Hitti J, Gloyd S, Manuel R, Osman N, et al. Antiretroviral-associated toxicity among HIV-1 seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr 2007 44 : 371 6.
9. British Columbia Ministry of Health, Canada. Priorities for action in managing the epidemics, HIV/AIDS in B.C. (2003-2007), 2006 Annual Progress Report. BC Ministry of Health. 2006 www.health.gov.bc.ca/hiv/priorities.html Accessed 21 April 2008.
10. British Columbia Center for Excellence in HIV/AIDS. HIV prevalence in British Columbia. 2005 www.cfenet.ubc.ca/content.php?id=18 Accessed 21 April 2008.
11. Division of Acquired Immunodeficiency Syndrome, USA. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. National Institute of Allergy and Infectious Disease, National Institute of Health (U.S.). 2004 www3.niaid.nih.gov/research/resources/DAIDSClinRsrch/PDF/Safety/ DAIDSAEGradingTable.pdf Accessed 21 April 2008.
12. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and role of hepatitis C or B virus infection. JAMA 2000 281 : 74 80.
13. Phanuphak N, Apornpong T, Teeratakulpisarn S, Chaithongwongwatthana S, Taweepolcharoen C, Mangclaviraj S, et al. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women. HIV Med 2007 8 : 357 66.
14. Martínez E, Blanco JL, Arnaiz JA, Pérez-Cuevas JB, Mocroft A, Cruceta A, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001 15 : 1261 8.
15. João EC, Calvet GA, MEnezes JA, D'Ippolito MM, Cruz MLS, Salgado LAT, et al. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. Am J Obstet Gynecol 2006 194 : 199 202.